2hOpinion
Dr. Robert R. Redfield: We need an urgent and unified response to the coming Alzheimerās crisis
The roadmap to fighting Alzheimerās disease is a matter of updating government policy to match the current science.
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
Patritumab deruxtecan shows meaningful clinical activity in heavily pretreated patients with metastatic breast cancer and ...
The approval marks the start of human testing for the experimental vaccine, which is designed to strengthen immune protection in respiratory tract.
A light pulse redirects electrons in an ultrathin layered material, creating a stable new state without heat or damage and ...
Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, /PRNewswire/ -- On ...
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...
As deadly drug overdoses climbed across Canada, decision-makers faced political backlash for funding programs that gave drug ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsDavid Dodd - Chairman, President & CEOMark Reynolds ...
A bench of Justices Surya Kant and Joymalya Bagchi asked the poll panel to respond to the fresh petitions in two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback